The collaboration will deploy FDA-cleared slide scanners across anatomic pathology services to support AI integration and address pathologist shortage.
Labcorp announced a collaboration with Roche to implement the company’s US Food and Drug Administration-cleared VENTANA DP 600 and DP 200 slide scanners across its anatomic pathology services. The investment enables pathologists to diagnose patients using digital images and supports future artificial intelligence (AI) integration.
The digital pathology workflow converts glass slides into high-resolution digital images that can be viewed using conventional PC workstations rather than microscopes. The technology allows pathologists to analyze and share images from any location, eliminating reliance on physical slides and enabling operations across different sites.
“Labcorp is committed to advancing its diagnostic capabilities through the adoption of innovative technologies,” says Marcia Eisenberg, PhD, Labcorp’s chief scientific officer, in a release. “Integrating digital slide scanning into our pathology workflow will help improve accuracy, streamline operations, and enable future AI-driven insights.”
Addressing Critical Workforce Shortage
The initiative addresses a projected shortage of nearly 5,700 pathologists by 2030 in the US, while demand for diagnostic services continues to grow due to an aging population and increasing incidence of cancer and other diseases.
Digital pathology technology allows for more efficient data sharing, centralized review, and faster decision-making. Labcorp already uses digital pathology technology globally to support clinical trials through its Biopharma Laboratory Services business segment.
“We look forward to expanding our collaboration with Labcorp to advance the digital transformation of their pathology labs,” says Michael Rivers, life cycle leader for digital pathology at Roche Tissue Diagnostics, in a release. “This collaboration, which combines Labcorp’s strength in diagnostic services with Roche’s expertise in digital pathology solutions, holds the potential to create new opportunities for highly efficient, timely, and effective patient care.”
Building on Existing Partnership
The investment builds on Labcorp’s existing relationship with Roche and its digital pathology portfolio for the company’s oncology business. The collaboration represents part of Labcorp’s commitment to expanding digital capabilities across its Diagnostics and Biopharma Laboratory Services business segments.
Photo caption: Roche digital pathology technology
Photo credit: Roche
